Zobrazeno 1 - 10
of 178
pro vyhledávání: '"Ps 2"'
Autor:
Gounant, V. 1, *, Brosseau, S. 1, Guezour, N. 1, Vauchier, C. 1, Leite Ferreira, D. 1, Nicolas, L. 2, Guillerm, S. 3, Mordant, P. 4, Zalcman, G. 1
Publikováno v:
In Revue des Maladies Respiratoires Actualités October 2023 15(2) Supplement 1:S172-S184
Autor:
Wallrabenstein, Till a, b, Mamot, Maximilian a, Daetwyler, Eveline a, König, David a, Rothschild, Sacha I. a, c, ∗
Publikováno v:
In JTO Clinical and Research Reports May 2023 4(5)
Autor:
Till Wallrabenstein, MD, Maximilian Mamot, MSc, Eveline Daetwyler, MD, David König, MD, Sacha I. Rothschild, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100509- (2023)
Introduction: On the basis of the landmark trial KEYNOTE-189 (KN-189), pembrolizumab plus chemotherapy has become the standard-of-care first-line treatment for patients with advanced nonsquamous NSCLC without oncogenic driver alterations.KN-189 inclu
Externí odkaz:
https://doaj.org/article/28b5722b324a48098ada0dc31a3f7a76
Autor:
Li, Xuefu a, 1, Wang, Jun a, 1, Ba, Wanyu a, Zhang, Suqiu a, Lin, Zhenxian b, Gao, Ming c, Tian, Hua a, ∗, Ru, Shaoguo a
Publikováno v:
In Chemosphere January 2022 286 Part 3
Autor:
Anant Ramaswamy, Kripa Bajaj, Vineet Talwar, Kumar Prabhash, Ullas Batra, Boman Dhabhar, Mansi Sharma, Nikhil Ghadyalpatil, Satish CT, Gautam Goyal, Javvid Muzamil, Amit Bhatt, Parveen Jain, Anantbhushan Ranade, Mangesh Kamath, Jayant Pundlik Gawande, Ravi Thippeswamy, Jimmy Mirani, Neelesh Reddy, Sandip Ganguly, Sourav Kumar Mishra, Irappa Madabhavi, Shashidhara HP, Soumya Surath Panda, Shekar Patil, Prabhat Bhargava, Vikas Ostwal
Publikováno v:
South Asian Journal of Cancer, Vol 11, Iss 01, Pp 024-030 (2022)
Abstract Vikas Ostwal Background Ramucirumab is considered a standard of care as second-line therapy (CT2) in advanced gastric cancers (AGCs). The aim of this study was to assess practice patterns and outcomes with ramucirumab among Indian patients
Externí odkaz:
https://doaj.org/article/fd744a65e57f4351b325109ee0646245
Autor:
Li, Xuefu a, Ru, Shaoguo a, Tian, Hua a, Zhang, Suqiu a, Lin, Zhenxian b, Gao, Ming c, Wang, Jun a, ⁎
Publikováno v:
In Science of the Total Environment 25 November 2021 797
Publikováno v:
In Advances in Medical Sciences September 2021 66(2):381-387
Autor:
Facchinetti, Francesco a, b, ∗, Mazzaschi, Giulia a, Barbieri, Fausto c, Passiglia, Francesco d, Mazzoni, Francesca e, Berardi, Rossana f, Proto, Claudia g, Cecere, Fabiana Letizia h, Pilotto, Sara i, Scotti, Vieri j, Rossi, Sabrina k, Del Conte, Alessandro l, Vita, Emanuele m, Bennati, Chiara n, Ardizzoni, Andrea o, Cerea, Giulio p, Migliorino, Maria Rita q, Sala, Elisa r, Camerini, Andrea s, Bearz, Alessandra l, De Carlo, Elisa l, Zanelli, Francesca t, Guaitoli, Giorgia c, Garassino, Marina Chiara g, Ciccone, Lucia Pia j, Sartori, Giulia i, Toschi, Luca k, Dall’Olio, Filippo Gustavo o, Landi, Lorenza n, Pizzutilo, Elio Gregory p, u, Bartoli, Gabriele q, Baldessari, Cinzia c, Novello, Silvia d, Bria, Emilio m, Cortinovis, Diego Luigi r, Rossi, Giulio v, Rossi, Antonio w, Banna, Giuseppe Luigi x, Camisa, Roberta a, Di Maio, Massimo y, Tiseo, Marcello a, z
Publikováno v:
In European Journal of Cancer May 2020 130:155-167
Autor:
Kyoichi Kaira, Atsuto Mouri, Shingo Kato, Kenichi Yoshimura, Hiroshi Kagamu, Kunihiko Kobayashi
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Durvalumab is a standard drug used during maintenance therapy after chemoradiotherapy in patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, little is known about the clinical benefits of durvalumab afte
Externí odkaz:
https://doaj.org/article/0eb16190376b4aae9140810ed4786f90